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Abstract
Background:  Enteral feeding of very low birth weight (VLBW) infants is a challenge, since
metabolic demands are high and administration of enteral nutrition is limited by immaturity of the
gastrointestinal tract. The amino acid glutamine plays an important role in maintaining functional
integrity of the gut. In addition, glutamine is utilised at a high rate by cells of the immune system. In
critically ill patients, glutamine is considered a conditionally essential amino acid. VLBW infants may
be especially susceptible to glutamine depletion as nutritional supply of glutamine is limited in the
first weeks after birth. Glutamine depletion has negative effects on functional integrity of the gut
and leads to immunosuppression. This double-blind randomised controlled trial is designed to
investigate the effect of glutamine-enriched enteral nutrition on feeding tolerance, infectious
morbidity and short-term outcome in VLBW infants. Furthermore, an attempt is made to elucidate
the role of glutamine in postnatal adaptation of the gut and modulation of the immune response.
Methods: VLBW infants (gestational age <32 weeks and/or birth weight <1500 g) are randomly
allocated to receive enteral glutamine supplementation (0.3 g/kg/day) or isonitrogenous placebo
supplementation between day 3 and 30 of life. Primary outcome is time to full enteral feeding
(defined as a feeding volume ≥ 120 mL/kg/day). Furthermore, incidence of serious infections and
short-term outcome are evaluated. The effect of glutamine on postnatal adaptation of the gut is
investigated by measuring intestinal permeability and determining faecal microflora. The role of
glutamine in modulation of the immune response is investigated by determining plasma Th1/Th2
cytokine concentrations following in vitro whole blood stimulation.
Background
Enteral feeding of very low birth weight (VLBW) infants is
a challenge, since metabolic demands are high and
administration of enteral nutrition is limited by immatu-
rity of the gastrointestinal tract. In particular, small for
gestational age VLBW infants may have impaired gut func-
tion, as fetal blood flow to heart, brain and adrenals is
compensatory increased, while other organs including the
Published: 01 September 2004
BMC Pediatrics 2004, 4:17 doi:10.1186/1471-2431-4-17
Received: 12 August 2004
Accepted: 01 September 2004
This article is available from: http://www.biomedcentral.com/1471-2431/4/17
© 2004 van den Berg et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pediatrics 2004, 4:17 http://www.biomedcentral.com/1471-2431/4/17
Page 2 of 7
(page number not for citation purposes)
gastro-intestinal tract are relatively hypoperfused in intra-
uterine growth retardation [1].
Experimental studies have shown that the amino acid
glutamine plays an important role in maintaining func-
tional integrity of the gut [2-5]. Glutamine serves as fuel
for enterocytes [2] and provides nitrogen for the synthesis
of amino sugars, involved in maintenance of tight junc-
tions [3] and mucin synthesis [4]. Moreover, glutamine
has a stimulatory and regulatory effect on mucosal cell
proliferation and differentiation [5].
Glutamine is not only utilised at a high rate by intestinal
epithelium but also by cells of the immune system. In
vitro studies have shown that increasing availability of
glutamine stimulates proliferation of T-lymphocytes in
response to T-cell mitogens [6], phagocytosis and antigen
presentation by monocytes [7] and Th1 cytokine response
[8].
In critically ill patients, endogenous glutamine synthesis
cannot meet increased demand and for this reason
glutamine is considered a conditionally essential amino
acid [9]. VLBW infants may be especially susceptible to
glutamine depletion as placental supply suddenly ceases
at birth, tolerance of enteral nutrition is limited and
parenteral nutrition does not contain glutamine for solu-
bility and stability reasons. Glutamine depletion has neg-
ative effects on the functional integrity of the gut [10] and
leads to immunosuppression [11].
Studies in adults have shown that glutamine supplemen-
tation decreases mortality in critically ill adults [12], infec-
tious morbidity in recipients of bone marrow
transplantation [13] and multiple trauma patients [14]
and length of hospital stay in surgical patients [15]. In
VLBW infants, only two studies have investigated efficacy
of glutamine supplementation [16,17]. In the study of
Lacey et al [16], 78 VLBW infants at high risk of develop-
ing necrotising enterocolitis (birth weight 530–1250 g)
were randomised to receive either standard or glutamine-
supplemented parenteral nutrition. After exclusion of 34
infants, 22 treated and 22 control infants were compared
for length of stay, days on total parenteral nutrition, days
on the ventilator and infectious morbidity. In infants with
a birth weight ≥ 800 g no effect of glutamine supplemen-
tation was found. However, in infants with a birth weight
<800 g glutamine supplementation was associated with
shorter time to full enteral nutrition, fewer days on
parenteral nutrition, fewer days on ventilatory support
and reduced length of stay. Incidence of positive blood
cultures and rate of weight gain were not different in
glutamine and control groups. Neu et al [17] performed a
randomised controlled trial of glutamine-enriched enteral
nutrition in 68 VLBW infants with a gestational age of 24–
32 weeks and a birth weight of 500–1250 g. Analysis was
performed in 66 infants on an intention to treat basis.
Feeding tolerance (as measured by number of days on
which feeding had to be withheld) was better in the
glutamine group compared to the control group. In addi-
tion, after adjusting for birth weight the odds ratio of
developing sepsis was 3.8 for the control group compared
to the glutamine group. Average weight at different time
intervals and length of stay were not different between the
groups. Although some methodological concerns can be
raised (the sample size of both studies is small; Lacey et al
[16] did not perform analysis on an intention to treat
basis), these studies suggest that glutamine supplementa-
tion enhances feeding tolerance and decreases infectious
morbidity in VLBW infants.
The current double-blind randomised controlled trial is
designed to determine the effect of glutamine-enriched
enteral nutrition on feeding tolerance in a sufficient large
population VLBW infants. We hypothesise that time to
full enteral feeding is shorter in infants who receive
glutamine-enriched nutrition compared to infants in the
control group. Furthermore, infectious morbidity and
short-term outcome are evaluated.
To elucidate the effect of glutamine-enriched enteral
nutrition on the functional integrity of the gut, intestinal
permeability for macromolecules is measured. As part of
the postnatal adaptation of the gut, the intestinal permea-
bility decreases during the first days of life [18]. We
hypothesise that glutamine-enriched enteral nutrition
stimulates postnatal adaptation of the gut, reflected by a
larger decrease in intestinal permeability. Another aspect
of postnatal adaptation of the gut is the development of
intestinal microflora. In VLBW infants, the colonisation
by bacteria (including beneficial Bifidobacterium  and
Lactobacillus  species [19,20]) commonly present in
healthy breast fed infants is delayed [21]. Intestinal mucin
is an important site for bacterial adhesion and colonisa-
tion [22]. Glutamine may improve mucin quality [4] and
consequently influence bacterial colonisation. We
hypothesise that glutamine-enriched enteral nutrition
stimulates the presence of Bifidobacterium and Lactobacillus
species in the intestinal microflora. Intestinal microflora
is investigated by determining faecal microflora with a
culture independent technique.
The effect of glutamine-enriched enteral nutrition on the
immune response is investigated by determining plasma
T-helper type 1 (Th1) and T-helper type 2 (Th2) cytokine
concentrations following in vitro whole blood stimula-
tion. As pregnancy is associated with skewing towards Th2
immunity [23], Th2 cytokine responses dominate the
neonatal immune response [24]. Exposure to microbes
stimulates Th1 cytokine responses and deviates theBMC Pediatrics 2004, 4:17 http://www.biomedcentral.com/1471-2431/4/17
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neonatal immune response towards balanced Th1/Th2
cytokine responses [24]. We hypothesise that glutamine-
enriched enteral nutrition contributes to balanced Th1/
Th2 cytokine responses by stimulating the Th1 cytokine
response [8].
To assess safety of glutamine-enriched enteral nutrition,
plasma amino acid profiles are determined. We hypothe-
sise that plasma amino acid profiles in glutamine and
control groups will not differ during the study period. In
addition, to exclude negative effects of glutamine-
enriched enteral nutrition on neurodevelopmental out-
come, neuromotor development at the corrected age of 1
and 2 years and mental/motor development at the cor-
rected age of 2 years are assessed.
In conclusion, this double-blind randomised controlled
trial aims to determine the effect of glutamine-enriched
enteral nutrition on feeding tolerance, infectious morbid-
ity and short-term outcome in VLBW infants. In addition,
an attempt is made to elucidate the role of glutamine in
postnatal adaptation of the gut and modulation of the
immune response.
Methods
The study is designed as a double-blind randomised clin-
ical trial. The national central committee on research
involving human subjects and the medical ethical review
board of our hospital approved the study protocol.
Study population
Infants with a gestational age <32 weeks and/or birth
weight <1500 g admitted to the level III neonatal intensive
care unit (NICU) of the VU University Medical Center,
Amsterdam, are eligible for participation in the study.
Written informed consent is obtained from all parents.
Exclusion criteria are: major congenital or chromosomal
anomalies, death <48 h after birth, transfer to another
hospital <48 h after birth and admission from an extrare-
gional hospital.
Treatment allocation and blinding
To balance birth weight distribution into treatment
groups, each infant is stratified to one of three birth
weight groups (<799 g, 800–1199 g, ≥ 1200 g) and ran-
domly allocated to treatment <48 hours after birth. An
independent researcher uses a computer-generated ran-
domisation table based on blocks of four (provided by
Nutricia Nederland BV, Zoetermeer, The Netherlands) to
assign infants to treatment A or B, which correspond to
batch numbers on the nutrition products. Investigators,
parents, medical and nursing staff are unaware of treat-
ment allocation. The code for the batch numbers is bro-
ken after data analysis is performed.
Treatment
Glutamine powder contains 82% L-glutamine and 18%
glucose (nitrogen 15.5 wt/wt%; 371 kcal/100 g), whereas
the isonitrogenous control powder contains 100% L-
alanine (nitrogen 15.7 wt/wt%, 435 kcal/100 g). The two
powders are indistinguishable by appearance, colour and
smell. During the study period, glutamine and control
powder are monitored for stability and microbiological
contamination.
Between days 3 and 30 of life, supplementation is admin-
istered in increasing doses to a maximum of 0.3 g/kg
glutamine per day in the glutamine group. Initially, the
supplementation dose is based on birth weight. After 2
weeks the dose is adjusted to actual weight. Two members
of the nursing staff daily add supplementation to breast
milk or to preterm formula (Nenatal®, Nutricia Nederland
B.V., Zoetermeer, The Netherlands), according to the par-
ents' choice. Per 100 ml, Nenatal® provides 78 kcal, 2.1 g
protein (casein-whey protein ratio 40:60), 4.4 g fat and
7.5 g carbohydrate. Nenatal® does not contain free L-
glutamine. When infants are transferred to other hospitals
before the end of the study, the protocol is continued
under supervision of the principal investigator.
Nutritional support
Protocol guidelines for the introduction of parenteral and
enteral nutrition follow current practice at our NICU.
Administration of parenteral nutrition starts at day 2 and
will be advanced gradually until amino-acid intake
reaches 3 g/kg/day at day 6. Parenteral nutrition is discon-
tinued if enteral feeding reaches a volume of approxi-
mately 150 mL/kg/day. Parenteral nutrition, an all-in-one
mixture provided by the hospital pharmacy, contains per
100 mL 54 kcal, 8.5 g glucose, 1.7 g amino acids and 1.7
g lipids. If necessary, glucose, amino acids and lipids are
given in separate solutions.
Guidelines for the introduction of enteral nutrition are as
follows: 1. minimal enteral nutrition starts at day 1 (6–12
mL daily); 2. enteral nutrition is advanced either from day
3 or from day 5 in case of complications: BW <p10, GA
<26 weeks, Apgar score at 5 minutes <6, umbilical artery
pH <7.10 or base deficit >10 mmol/L; 3. feeding is
advanced at a dose of 15–20 mL/kg/day to a maximum of
150 mL/kg/day (based on actual weight). Furthermore,
guidelines for reduction/withholding of enteral feeding
are: 1. enteral feeding is reduced/withheld in case of gas-
tric residuals (> total volume of past 2 feedings), bilious
residuals, emesis, ileus or necrotising enterocolitis Bell's
stage  ≥ II [25]; 2. when signs of feeding intolerance
resolve, feeding is advanced in the volume given before
reduction/withholding within 2 days.BMC Pediatrics 2004, 4:17 http://www.biomedcentral.com/1471-2431/4/17
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For each infant in the study a feeding schedule is pro-
posed, based on birth weight and the guidelines as men-
tioned above. However, the staff of our NICU has final
responsibility for the administration of parenteral nutri-
tion and advancement of enteral feeding.
Study outcome measures
Study outcome measures
Primary outcome of the study is time to full enteral feed-
ing, defined as a feeding volume ≥ 120 mL/kg/day. Fur-
thermore, other parameters of feeding tolerance,
infectious morbidity, and short-term outcome are evalu-
ated (Table 1). In addition to clinical outcome, intestinal
permeability, faecal flora, plasma Th1/Th2 cytokine con-
centrations and plasma amino acid profiles are deter-
mined during the 30 day study period (Table 2).
Clinical outcome measures
The following perinatal characteristics are registered to
assess prognostic similarity: maternal age and race, obstet-
ric diagnosis, administration of antenatal steroids and
antibiotics, mode of delivery, sex, gestational age, birth
weight, birth weight <p10, Apgar scores, pH of the umbil-
ical artery, clinical risk index for babies [26] and adminis-
tration of surfactant.
During the study period actual intake of enteral and
parenteral nutrition, powder supplementation and type of
feeding (breast milk or preterm formula) are recorded
daily.
Evaluation of medical records for the presence of serious
infections is performed by one investigator/neonatolo-
gist, unaware of treatment allocation. Serious infections
include sepsis, meningitis, pyelonephritis, pneumonia,
and arthritis. Sepsis work-up consists of blood,
cerebrospinal fluid and urine (suprapubic bladder tap)
culture. Sepsis is defined as the combination of a positive
blood culture and the presence of at least two clinical
signs (body temperature <36.5°C or >37.5°C, hypoten-
sion, tachycardia, apnoeic attacks, feeding problems, irri-
tability or apathy). Meningitis is diagnosed when micro-
organisms are cultured in the cerebrospinal fluid.
Pyelonephritis is diagnosed when both urine culture and
dimercaptosuccinic acid (DMSA) renal scan are positive.
Pneumonia is defined as the combination of a positive
culture of tracheal aspirate, bronchial secretion or sputum
and the presence of at least one clinical sign in ventilated
infants (purulent sputum, changed sputum characteristics
or deterioration of ventilation settings) or at least two
clinical signs in non-ventilated infants (tachypnea, cyano-
sis, wheezing/rales/crepitation or purulent sputum/
changed sputum characteristics). Arthritis is defined as the
combination of a positive culture of intra-articular fluid
and the presence of signs of articular inflammation.
Postnatal adaptation of the gut
The effect of glutamine-enriched enteral nutrition on
postnatal adaptation of the gut is studied by measuring
intestinal permeability and by determining faecal flora.
Table 1: Clinical outcome measures
Remarks
Feeding tolerance
Enteral feeding >120 mL/kg/day Primary outcome
Age at finishing parenteral nutrition
Days of no enteral feeding during study period
Necrotising enterocolitis Bell et al [25]
Infectious morbidity
Serious infections
Number of infectious episodes
Cultured micro-organisms
Short-term outcome
Weight z scores at birth, day 30 and at discharge Usher et al [33]
Patent ductus arteriosus
Ventilatory support
Use of oxygen at postmenstrual age of 36 weeks Jobe et al [34]
Intraventricular hemorrhage Papile et al [35]
Retinopathy of prematurity Committee for ROP [36]
Death
Age at discharge from NICU and at discharge home
ROP = retinopathy of prematurity; NICU = neonatal intensive care unit.BMC Pediatrics 2004, 4:17 http://www.biomedcentral.com/1471-2431/4/17
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Intestinal permeability is measured by the sugar absorp-
tion test, as previously described [18]. After instillation of
the test solution, 2 ml/kg by nasogastric tube, urine is col-
lected for 6 hours. After collection, 0.5 ml chlorohexidine
digluconate 20% (preservative) is added to the urine and
samples are stored at -20°C until analysis. Lactulose and
mannitol concentrations (mmol/mol creatinine) are
measured by gas chromatography as previously described
[27]. The lactulose/mannitol ratio is used as a measure of
intestinal permeability.
Faecal samples are stored at -20°C until analysis by fluo-
rescent in situ hybridisation (FISH) using specific 16S
rDNA-targeted probes as described by Harmsen et al [28].
Immune response
The effect of glutamine enriched-enteral nutrition on the
immune response is investigated by determining plasma
Th1/Th2 cytokine concentrations following in vitro whole
blood stimulation. Heparinized blood (0.5 mL), diluted
1:1 in sterile medium (RPMI 1640 without L-glutamine,
Gibco, Paisley, United Kingdom) is stimulated for 24 h at
37°C in the presence of anti-CD3/anti-CD28 (Central
Laboratory of the Netherlands Red Cross Blood Transfu-
sion service, Amsterdam, the Netherlands) and Escherichia
coli lipopolysaccharide (concentration 1:1000 both). After
incubation, blood is centrifugated, supernatant is col-
lected and stored at -20°C until analysis. Th1 cytokines
IFN-γ, TNF-α, IL-2 and Th2 cytokines IL-4, IL-5 and IL-10
are measured by cytometric bead array (BD biosciences,
Alphen aan den Rijn, the Netherlands).
Safety
Safety of enteral glutamine supplementation in a dosage
of 0.3 g/kg/day is investigated by determination of plasma
amino acid profiles. Immediately after withdrawal,
heparinized blood (0.5 mL) is centrifuged at 10000 rpm
for 4 minutes. Plasma is deproteinized by sulfosalicylic
acid (2mg/100 µL) and stored at -70°C until analysis.
Amino acid profiles are determined by high-performance
liquid chromatography as described by Teerlink et al [29].
To investigate neurodevelopmental outcome, neuromo-
tor development at the corrected age of 1 and 2 years [30]
and mental/motor development at the corrected age of 2
years are assessed [31].
Sample size
We have calculated that a sample size of 102 infants is
necessary to detect a difference of at least 2.5 days in time
to full enteral feeding, assuming a SD of 4.5 days (two-
tailed α = 0.05, β = 0.20). The SD value is based on an ret-
rospective analysis of time to full enteral feeding in infants
with GA <32 weeks and/or BW <1500 g admitted to our
NICU in 1998.
Statistical analysis
To determine whether randomisation is successful, prog-
nostic similarity (perinatal and nutritional characteristics)
between treatment groups is assessed. The Students' t-test,
Mann-Whitney U test, and chi-square test or Fisher's exact
test are used to compare continuous normally distributed
data, nonparametric continuous data and dichotomous
data respectively.
Cox regression is performed to examine the effect of
glutamine-enriched enteral nutrition on time to full
enteral feeding. Logistic regression is performed to exam-
ine whether glutamine-enriched enteral nutrition influ-
ences the incidence of serious infections. In an additional
analysis, adjustments are made for possible confounding
factors as administration of antenatal corticosteroids,
birth weight <p10, administration of breast milk and
other prognostic factors that may be different between
treatment groups.
Analyses of secondary outcomes (only crude) is per-
formed by Mann-Whitney U test, chi-square test or
Fisher's exact test and log rank test for nonparametric
continuous data, dichotomous data, and time-dependent
data respectively.
Generalised estimated equations for longitudinal analysis
[32] are used to analyse changes over time in intestinal
permeability, faecal microflora, plasma Th1/Th2 cytokine
concentrations and plasma amino acid profiles.
Table 2: Study schedule
< 48 h day 7 day 14 day 30
A m i n o  a c i d  p r o f i l e xxxx
Intestinal permeability xxxx
F a e c a l  f l o r a xxxx
Th1/Th2 cytokine profile x x x -BMC Pediatrics 2004, 4:17 http://www.biomedcentral.com/1471-2431/4/17
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Distribution of optimal and non-optimal neuromotor
development and normal and abnormal mental/motor
development in glutamine and control groups is exam-
ined by logistic regression with adjustments for possible
confounding factors as gestational age and birth weight.
All statistical analyses are performed on an intention to
treat basis. In addition, alternative per protocol analyses
are performed, excluding all patients who are not treated
according to protocol, defined as more than 3 consecutive
days or a total of 5 days on minimal enteral feeding or
without supplementation.
A p value <0.05 is considered significant (two-tailed).
SPSS 9.0 (SPSS Inc., Chicago, IL, USA) and STAT 7.0 (Stat-
Corp LP, College Station, TX, USA) are used for data
analysis.
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